BHVN Biohaven Pharmaceutical Holding Company Ltd.

44.8
-0.92  -2%
Previous Close 45.72
Open 46
Price To Book 23.83
Market Cap 2,307,272,307
Shares 51,501,614
Volume 118,454
Short Ratio 2.99
Av. Daily Volume 1,095,122

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2/3 trial enrolling.
TRORILUZOLE
Obsessive compulsive disorder (OCD)
NDA acceptance announced November 26, 2018. PDUFA date not supplied. Estimate July 25, 2019.
BHV-0223
Amyotrophic lateral sclerosis (ALS)
Phase 3 top-line data due 4Q 2019.
Rimegepant
Migraine - preventative
NDA filing submitted 2Q 2019.
Rimegepant
Acute treatment of migraine
Phase 2 enrolment to be completed 4Q 2019. Futility analysis also due 4Q 2019.
TRORILUZOLE
Alzheimer’s disease
Phase 3 enrolment to be completed by the end of 2019.
TRORILUZOLE
Generalized anxiety disorder (GAD)
Phase 3 trial to be initiated 3Q 2019.
Verdiperstat
Multiple system atrophy (MSA)
Phase 2/3 top-line data due 4Q 2019.
BHV-3500
Acute treatment of migraine
Phase 3 enrolment to be completed 1Q 2020.
TRORILUZOLE
Spinocerebellar Ataxia (SCA)
Phase 2 commencement of enrolment announced July 1, 2019.
Rimegepant
Refractory trigeminal neuralgia

Latest News

  1. Biohaven's Positive Phase 3 Trial of Rimegepant Zydis® Orally Dissolving Tablet for Acute Treatment of Migraine Published in The Lancet
  2. Biohaven Showcases Positive Data on Rimegepant, Oral CGRP Receptor Antagonist, with 16 Presentations at 2019 American Headache Society (AHS) Annual Scientific Meeting Demonstrating Efficacy in Multiple Patient Types and Long-term Safety
  3. Biohaven Launches 'Demand More' Campaign At 2019 American Headache Society Annual Scientific Meeting: Highlighting Patient Needs In Acute Treatment Of Migraine
  4. The Daily Biotech Pulse: Neurocrine's Parkinson's Drug Accepted For Review, Sunesis Offering, No Headaches For Biohaven's Migraine Drug
  5. Biohaven's Rimegepant Positive Phase 3 Trial For Acute Treatment Of Migraine Published In The New England Journal of Medicine
  6. 2 Single Hitters That Could Score With the 'Write' Strategy
  7. Biohaven Offering Seems to Make Sale Less Likely
  8. Weekly CFO Buys Highlight
  9. Biohaven Enrolls First Patient in Phase 2 Clinical Trial of Rimegepant, Oral CGRP Receptor Antagonist, for Treatment Refractory Trigeminal Neuralgia
  10. Biohaven Pharmaceutical Holding Co Ltd (BHVN) CEO Vlad Coric Bought $201,100 of Shares
  11. Biohaven To Present 16 Abstracts At 2019 American Headache Society (AHS) Annual Scientific Meeting Highlighting New Data With Rimegepant, Oral CGRP Receptor Antagonist
  12. Biohaven Announces Pricing Of $300 Million Public Offering Of Common Shares
  13. Migraine-Drug Deal Hype Turns Into a Giant Headache
  14. Here's Why Biohaven Pharmaceutical Plummeted Today
  15. The Daily Biotech Pulse: PhaseBio Pumped Up, Eiger Exults On Breakthrough Therapy Designation, Biohaven Slips On Stock Sale
  16. Should Biohaven Pharmaceutical Holding (NYSE:BHVN) Be Disappointed With Their 36% Profit?
  17. Biohaven Announces Proposed Public Offering Of Common Shares
  18. Why Alzheimer's Treatment Hopes Endure Despite High-Profile Drug Failures
  19. Hedge Funds Have Never Been This Bullish On Biohaven Pharmaceutical Holding Company Ltd. (BHVN)
  20. Options Traders Expect Huge Moves in Biohaven Pharmaceutical (BHVN) Stock